Table 2. Univariate analyses results of all laboratory tests by group (n=21).
| Characteristic | Normal group (n=19) | Abnormal group (n=2) | Univariate HR (95% CI) | Univariate p-value |
|---|---|---|---|---|
| Age (yr) | 45.26±11.05 | 32.00±11.31 | 0.909 (0.750~1.051) | 0.213 |
| Sex* | 0.288 | |||
| Male | 5 (26.3) | 2 (100) | 7.501 (0.610~1034.421) | |
| Female | 14 (73.7) | 0 (0) | ||
| Duration of disease (mo) | 107.21±107.73 | 109.00±151.32 | 0.997 (0.979~1.011) | 0.715 |
| PASI score* | 0.381 | |||
| ≤10 | 9 (47.4) | 0 (0) | 5.474 (0.414~769.510) | |
| >10 | 10 (52.6) | 2 (100) | ||
| Total medication period (d) | 766.53±582.44 | 719.00±425.68 | ||
| CsA medication period (d) | 521.84±533.43 | 269.50±84.15 | 0.996 (0.980~1) | 0.284 |
| CsA cumulative dose (g) | 123.11±192.68 | 45.13±19.62 | 1 (1~1) | 0.254 |
| MTX medication period (d) | 244.69±243.31 | 449.50±509.82 | 1.001 (0.996~1.004) | 0.730 |
| MTX cumulative dose (mg) | 415.95±416.16 | 760.00±832.97 | 1 (0.998~1.003) | 0.723 |
| Underlying diseases | ||||
| Diabetes* | 1 | 0 | 4.593 (0.032~87.481) | 0.511 |
| Hypertension* | 6 | 0 | 0.529 (0.004~6.863) | 0.742 |
| Dyslipidemia* | 1 | 0 | 4.593 (0.032~87.481) | 0.511 |
| Others*,† | 1 | 0 | - | - |
Values are presented as mean±standard deviation, number (%), or number only.
HR: hazard ratio, CI: confidence interval, PASI: psoriasis area and severity index, CsA: cyclosporine, MTX: methotrexate.
*Firth's correction was applied. †Angina.